drugset / Trial / NCT05385783
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
Phase 1/2
Completed
57 enrolled
Cybin IRL Limited
Clinilabs Drug Development Corporation · collabDrug Safety Navigator · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
Timeline
- Start
- 2022-08-02
- Primary completion
- 2023-10-16
- Completion
- 2024-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CYB003 | Unknown | — | Oral |